VACCIBODY
LIVE

Serial Number

79316187

Owner

NYKODE THERAPEUTICS ASA

Attorney

Michael A. Bondi

Filing Date

May 28, 2021

Add to watchlist:

No watchlists yet
View on USPTO

VACCIBODY Trademark

Serial Number: 79316187 • Registration: 6854571

VACCIBODY is a trademark filed by NYKODE THERAPEUTICS ASA on May 28, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

NYKODE THERAPEUTICS ASA (4 trademarks)

Gaustadalléen 21

Entity Type: 99

Vaccibody AS

Gaustadalléen 21

Entity Type: 99

Trademark Details

Filing Date

May 28, 2021

Registration Date

September 27, 2022

Published for Opposition

July 12, 2022

Goods & Services

Treatment of materials for use in production of pharmaceutical preparations; custom manufacturing of pharmaceuticals; custom manufacturing of chemical and biological preparations for treatment of cancer, preparations for treatment of tumors, immunotherapeutic preparations, anti-cancer preparations for injection, radioactive preparations for radiation treatment, radioactive pharmaceuticals, vaccines, preparations for treatment of viral diseases, preparations for treatment of allergies, preparations for treatment of autoimmune diseases, immunostimulants, biological preparations for treatment of viral diseases, biological preparations for treatment of allergies, biological preparations for treatment of autoimmune diseases and diagnostic preparations

Downloadable software and computer applications for use with immunotherapy for monitoring treatment progress and determining treatment success; downloadable software and computer applications for designing pharmaceuticals; downloadable software and computer applications for designing personalized medicines; downloadable software and computer applications for selection of antigens for designing pharmaceuticals

Sanitary preparations for medical purposes; dietetic foods adapted for medical and veterinary use; nucleic acids adapted for medical and veterinary use; dietary supplements for humans and animals; pharmaceutical preparations for treatment of immune diseases; pharmaceutical preparations for treatment of cancer; pharmaceutical preparations for treatment of tumors; anti-cancer pharmaceutical preparations for injections; radioactive preparations for radiation treatment; radioactive medicines; pharmaceutical preparations for treatment of infectious diseases; pharmaceutical preparations for treatment of viral diseases; biological preparations for treatment of cancer; biological preparations for treatment of infectious diseases; biological preparations for treatment of viral diseases; vaccines; immunostimulants; pharmaceutical preparations for treatment of allergies; biological preparations for treatment of allergies; pharmaceutical preparations for treatment of autoimmune diseases; biological preparations for treatment of autoimmune diseases

Promoting pharmaceutical, biological, diagnostic products, vaccines, anti-cancer pharmaceutical products and immunotherapeutic pharmaceuticals of others; retail store services in the field of pharmaceutical, biological diagnostic products, vaccines, anti-cancer pharmaceutical products and immunotherapy pharmaceuticals

Medical apparatus and instruments for administration of pharmaceuticals; medical apparatus and instruments for injection of pharmaceuticals; medical apparatus and instruments for dosing of pharmaceuticals; parts for all the aforementioned goods

Design and development of computer hardware and software; design, research and development of pharmaceuticals, preparations for cancer treatment, preparations for treatment of tumors, immunotherapeutic preparations, anti-cancer preparations for injection, radioactive preparations for radiation treatment, radioactive pharmaceuticals, vaccines, preparations for treatment of viral diseases, preparations for treatment of allergies, preparations for treatment of autoimmune diseases, immunostimulants, biological preparations for treatment of cancer, biological preparations for treatment of viral diseases, biological preparations for treatment of allergies, biological preparations for treatment of autoimmune diseases and diagnostic preparations; design and development of diagnostic equipment and medical instruments; research and development in the field of diagnostic preparations; design and development of medical techniques; research and development for the pharmaceutical industry; consultancy and information related to the aforesaid services

Filing History

TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 8, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Apr 8, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr 8, 2025 REAP
FINAL DECISION TRANSACTION PROCESSED BY IB
Feb 14, 2023 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jan 21, 2023 FICS
FINAL DISPOSITION PROCESSED
Jan 21, 2023 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Dec 27, 2022 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Sep 27, 2022 NRCC
REGISTERED-PRINCIPAL REGISTER
Sep 27, 2022 R.PR
CHANGE OF NAME/ADDRESS REC'D FROM IB
Jul 30, 2022 ADCH
NOTIFICATION PROCESSED BY IB
Jul 18, 2022 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 12, 2022 NPUB
PUBLISHED FOR OPPOSITION
Jul 12, 2022 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jun 29, 2022 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jun 29, 2022 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 22, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 7, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 13, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 12, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 12, 2022 TROA
REFUSAL PROCESSED BY IB
Apr 11, 2022 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 18, 2022 RFCS
REFUSAL PROCESSED BY MPU
Mar 18, 2022 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Feb 18, 2022 RFCR
NON-FINAL ACTION WRITTEN
Feb 17, 2022 CNRT
ASSIGNED TO EXAMINER
Feb 11, 2022 DOCK
CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED
Nov 9, 2021 CORR
CORRECTION TRANSACTION RECEIVED FROM IB
Sep 19, 2021 CRCV
APPLICATION FILING RECEIPT MAILED
Jul 31, 2021 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 27, 2021 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 22, 2021 REPR